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Background. Diphtheria is a vaccine-preventable disease that persists as a global health problem. An understanding of the pat-
tern of disease is lacking in low- and middle-income countries such as the Philippines.
Methods. We conducted a retrospective review of the clinical, microbiological, and epidemiological features of patients ad-
mitted with a clinical diagnosis of diphtheria to an infectious disease referral hospital in Metro Manila, the Philippines, between 2006 
and 2017. Cases were mapped and the distribution was compared with population density. Corynebacterium diphtheriae isolates 
from between 2015 and 2017 were examined by multilocus sequence typing (MLST).
Results. We studied 267 patients (range:12−54 cases/year) admitted between 2006 and 2017. The case fatality rate (CFR) 
was 43.8% (95% confidence interval, 37.8−50.0%). A higher number of cases and CFR was observed among children <10 years. 
Mortality was associated with a delayed admission to hospital and a lack of diphtheria antitoxin. Between 2015 and 2017 there were 
42 laboratory-confirmed cases. We identified 6 multilocus sequence types (STs). ST-302 was the most common (17/34, 48.6%), fol-
lowed by ST67 (7/34, 20%) and ST458 (5/34, 14%). Case mapping showed a wide distribution of diphtheria patients in Metro Manila. 
Higher case numbers were found in densely populated areas but with no apparent clustering of ST types.
Conclusions. Our analysis indicates that diphtheria remains endemic in Metro Manila and that the infection is frequently fatal 
in young children. Improved vaccine coverage and a sustainable supply of diphtheria antitoxin should be prioritized.
Keywords.  diphtheria; the Philippines; diphtheria antitoxin; MLST; vaccination.
Diphtheria is vaccine-preventable disease that remains a global 
health problem. Toxigenic Corynebacterium diphtheriae can 
cause an upper respiratory tract infection complicated by car-
diac, neurological, and renal manifestations associated with 
a high mortality. Transmission occurs by person-to-person 
route through close physical contact and respiratory droplet 
spread [1, 2]. Diphtheria incidence has steadily declined with 
the introduction of the Expanded Program on Immunization 
(EPI) and socioeconomic improvements [1]. Despite these ef-
forts, diphtheria remains endemic in areas with low vaccine 
coverage, poor hygiene conditions, and overcrowding [3, 4]. 
Recent outbreaks have been reported in Indonesia, Yemen, and 
Myanmar/Bangladesh [4–6].
An EPI program was established in the Philippines in 1976 
with a primary vaccine course of 3 diphtheria, pertussis and tet-
anus vaccine (DPT) doses given at 6, 10, and 14 weeks of age [7]. 
In 2013, a school-based immunization program was launched 
for children aged 6−7 years and 11−12 years [7, 8]. The World 
Health Organization (WHO) estimated the immunization cov-
erage for the primary series of diphtheria vaccination to be 86% 
in 2016. To our knowledge, the vaccine coverage for the booster 
doses in the Philippines has not officially been reported [9]. 
Despite these efforts, diphtheria cases continue to be reported 
[10]. According to WHO statistics, there were an average of 56 
(range, 0–188) annual cases reported between 2006 and 2017. 
The Philippines Department of Health (DOH) reported 104 to 
168 annual cases between 2014 and 2017 [10–12].
We conducted an observational study in the National 
Infectious Disease hospital (San Lazaro Hospital [SLH]) in 
Metro Manila to describe the clinical, microbiological, and ep-
idemiological characteristics of patients attending the hospital 
with clinically diagnosed and laboratory-confirmed diphtheria. 
We also aimed to understand the distributions of diphtheria 
cases by molecular types in Metro Manila.
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METHODS
We conducted the study at SLH, a 500-bed tertiary hospital 
specializing in infectious diseases in Metro Manila [11]. San 
Lazaro Hospital is the national referral center treating the lar-
gest number of diphtheria cases in the Philippines.
We analyzed patients admitted to SLH with a discharge di-
agnosis of diphtheria (International Classification of Diseases, 
10th revision, code A36) over an 11.1-year period between 1 
January 2006 to 9 February 2017. The clinical diagnosis of diph-
theria was based on assessments by 2 attending physicians and 
defined as a respiratory illness consisting of pharyngitis, tonsil-
litis, or laryngitis and an adherent tonsillar or nasopharyngeal 
pseudomembrane. Demographic, epidemiological, and clinical 
data including the date of admission, age, sex, home location of 
the patient, and administration of diphtheria antitoxin (DAT) 
were extracted from the medical records. DAT was not avail-
able until March 2016 when the WHO and the DOH started to 
provide DAT.
In December 2015, the hospital established laboratory 
methods for C.  diphtheriae isolation and confirmation and 
started prospective data collection using structured question-
naire sheets for all patients with clinically suspected diphtheria. 
We analyzed these laboratory-confirmed cases separately. The 
immunization history was obtained by the questionnaire, and we 
requested family members to present the immunization cards.
Laboratory-confirmed cases were defined as a patient with 
a positive result of culture for C. diphtheriae and/or a tox-gene 
polymerase chain reaction (PCR)–positive result from throat or 
nasopharynx swab samples.
Throat or nasopharynx swab specimens were taken at the 
time of admission from all patients with clinically suspected 
diphtheria. Brain heart infusion (BHI) broth was used as trans-
port media. The swabs were inoculated to 5% sheep blood agar 
and selective Hoyle`s agar with potassium tellurite (Oxoid). 
Black suspect colonies on Hoyle’s media that were gram-pos-
itive bacilli were identified using MALDI Biotyper (Bruker 
Daltonics). The Minimum Inhibitory Concentrations (MICs) 
of penicillin G and erythromycin were determined by E-test 
strips according to manufacturer’s instructions (Biomerieux). 
Isolates were stored in glycerol broth at −80°C for subsequent 
tox-gene PCR.
We assessed the toxigenicity of the identified isolates by a 
PCR that detects the tox gene using a published method [13]. 
Direct toxin gene detection was also performed on the throat 
swabs. DNA was extracted from the 100-μL aliquot of the BHI 
transport broth using a QIAamp DNA Blood Mini Kit following 
the manufacturer’s instructions (Qiagen). DNA extracted from 
isolates was stored at −20°C using a DNA extraction kit (Wizard 
Genomic DNA Purification Kit; Promega) and transported to 
Nagasaki, Japan for multilocus sequence typing (MLST) as de-
scribed by Bolt et al [14]. Sequence types (STs) were assigned 
by the PubMLST database and added to this database (https://
pubmlst.org/cdiphtheriae/). We generated a phylogenetic tree 
by using Molecular Evolutionary Genetics Analysis (MEGA) 
software version MEGA 7.0.26 (https://www.megasoftware.
net/). A  maximum likelihood tree was constructed using the 
concatenated sequences (2544 nucleotides) of the 7 loci used in 
MLST. In the analysis, the publicly available sequence of 56/S 
(C. diphtheriae isolated in Poland, 1950) was added to the align-
ment as an outlier. We defined a clonal complex as a cluster of 
isolates sharing 6 out of 7 alleles. Clonal analysis was performed 
using eBURSTv3 (http://eburst.mlst.net/default.asp). We gener-
ated an eBURST diagram of C. diphtheriae to show relatedness 
between isolates in this study and 703 isolates previously regis-
tered in PubMLST (https://pubmlst.org/cdiphtheriae/).
We converted the home location of the patients with diph-
theria in Metro Manila into Global Positioning System (GPS) 
locations and conducted analysis using Geographic Information 
System (GIS) software (ArcGIS version 10.5; ESRI). Population 
data and basic maps were obtained from the PhilGIS (http://
www.philgis.org/gis-data), the Philippines Statistics Authority 
(https://psa.gov.ph/), and Esri (http://www.esri.com/software/
arcgis/arcgisonline/features/maps). We created a case map 
using GPS locations of clinically diagnosed diphtheria cases be-
tween January 2006 and December 2015 and culture-positive 
diphtheria cases by the STs between December 2015 and 
February 2017. We created a population-density map in Metro 
Manila and compared the distributions of the diphtheria cases 
with the population density. Kernel density analysis was used 
to determine hotspot areas of clinically diagnosed diphtheria 
cases between January 2006 and December 2015. We compared 
the distributions of culture-positive diphtheria by STs with the 
hotspot area created with the previously clinically diagnosed 
diphtheria cases.
We used Microsoft Access 2010 (Microsoft Corporation) for 
the data entry. Each case was given a study-specific identifying 
number. Statistical analyses were performed using Stata soft-
ware (version 13; StataCorp). We conducted a statistical analysis 
of patient characteristics using Fisher’s exact test for categorical 
variables and t test for continuous variables. We calculated risk 
ratios (RRs) of the effect of variables on fatal outcomes using 
an unadjusted logistic regression model. An adjusted logistic 
regression model was not used in this study because of the 
small sample size. Age groups were categorized into 0−4, 5−9, 
10−14, 15−20, and over 20 years. We report in accordance with 
the STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) statement.
Ethical approval was obtained from the Research and Ethical 
Review Board of SLH, the Philippines (reference number:2016–
015-E), and the Institutional Review Board of the Institute of 
Tropical Medicine, Nagasaki University, Japan (170707169). 
Both review boards agreed that consent from the patients was 
not required as this study consisted of analysis of data previ-
ously collected as part of standard clinical management.
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RESULTS
Between 1 January 2006 and 9 February 2017, a total of 267 
patients (mean, 24 cases/year; range, 12−54 cases/year) with 
clinically diagnosed diphtheria were admitted to SLH (Table 1, 
Supplementary Figure 1). The majority of cases were children 
younger than 15  years old (231 cases, 86.5%). Children aged 
5−9 years (103 cases, 38.6%) were most common, followed by 
children younger than 5 years (83 cases, 31.1%).
A total of 117 patients died in the hospital (43.8%; 95% con-
fidence interval [CI], 37.8−50.0) (Table  1). The case fatality 
rate (CFR) was highest (60.2%; 48.9−70.8%) among children 
younger than 5 years, followed by those aged 5−9 years (44.7%; 
34.9−54.8%) (Supplementary Figure 2). The lowest CFR was 
observed among subjects aged 15−19 years (17.4%; 5.0−38.8%). 
There was no significant difference in the CFR by sex. There 
was a significantly lower CFR among patients given DAT as 
part of their clinical management compared with patients not 
given DAT (103/216 [47.7%; 40.9−54.6%] vs 14/51 [27.5%; 
15.9−41.7%]; P < .01).
After introducing enhanced laboratory testing on 1 
December 2015, there were 68 patients with clinically diag-
nosed diphtheria, of whom 42 were confirmed by laboratory 
testing (Table 2). Corynebacterium diphtheriae was isolated in 
35 patients, and all isolates had a positive tox-gene PCR result. 
A further 7 patients had a positive tox-gene PCR on the throat 
swab but a negative culture result. There were 33 (94.3%) iso-
lated strains susceptible to penicillin G (MIC  ≤0.12  mg/dL) 
and 2 (5.7%) strains intermediate according to the Clinical 
Laboratory Standards Institute (CLSI M45 2016)  guideline. 
Most isolates were susceptible to erythromycin, but 1 isolate 
was resistant (MIC = 2 mg/dL) [15].
We observed 18 deaths among the 42 patients with 
laboratory-confirmed diphtheria, giving a CFR of 42.8% 
(95% CI, 27.7−59.0%). The CFRs among children younger 
than 5  years (60%; 32.3−83.7%) and those aged 5−9  years 
(80%; 28.4−99.5%) were higher compared with patients aged 
10−14 years (25%; 5.5−57.2%) and 15−19 years (0%), although 
the CIs were wide due to the small sample size (Supplementary 
Table 2, Supplementary Figure 3). Of patients, 33.3% were 
living outside Metro Manila and they had significantly higher 
CFRs compared with patients living in Metro Manila (64.3% 
[35.1−87.2%] vs 32.1% [15.9−52.4%]; P  =  .049). Patients at-
tending the hospital within 4 days after onset of symptom had 
a significantly lower CFR than those admitted after 5 days or 
more (28% [12.1−49.4%] vs 64.7% [38.3−85.8%]; P = .03). The 
RR of death among patients with a chronic disorder compared 
with patients without a chronic disorder was significantly in-
creased (RR, 2.11; 95% CI, 1.16−3.86).
Twenty (47.6%) of the 42 patients with laboratory-confirmed 
diphtheria reported having received 3 primary doses of DPT 
vaccine, but only 8 were confirmed by inspection of their im-
munization record card. Among the fully immunized patients 
confirmed by their immunization card, there was 1 death of a 
9-year old patient. There was no significant difference in the 
CFR between subjects with a history of receiving 3 doses of pri-
mary vaccinations than in those without any history of the vac-
cine (Table 2). None of the patients reported receiving a booster 
dose of diphtheria vaccine. All cases were treated with peni-
cillin G. Among the 30 patients who received DAT, 11 (CFR, 
36.7%; 19.9−56.1%) died compared with 7 deaths among the 
12 who did not receive DAT due to limited availability (58.3%; 
27.7−84.8%) (P = .17).
Among 34 isolates available for MLST testing, a total of 
7 STs and 4 isolates without ST identifications were found 
(Supplementary Table 1). Sequence types of 4 isolates were 
not identified because 1 allelic profile was not generated by the 
PubMLST database. ST-302 was the most common ST type 
(n = 17; 48.6%), followed by ST-67 (7 cases, 20%) and ST-458 
Table 1. Comparison of the Characteristics of Patients Admitted to San Lazaro Hospital, Manila, the Philippines, With Clinically Diagnosed Diphtheria 
Between 1 January 2006 and 9 February 2017 According to Whether They Survived or Died
Total, N or n (%) Survived, n Died, n Mortality, % P
Totala 267 150 117 43.8  
Sex
 Female 145 (54.3) 82 63 43.5 .902
 Male 122 (45.7) 68 54 44.3
Age group
 <5 years 83 (31.1) 33 50 60.2 <.01
 5–9 years 103 (38.6) 57 46 44.7
 10–14 years 45 (16.9) 34 11 24.4
 15–19 years 23 (8.6) 19 4 17.4
 ≥20 years 13 (4.9) 7 6 46.2
DAT treatment given during the admission
 DAT not given 216 (80.9) 113 103 47.7 <.01
 DAT given 51 (19.1) 37 14 27.5  
Abbreviation: DAT, diphtheria antitoxin.
aThe observation period is 11.1 year between 1 January 2006 and 9 February 2017.
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(5 cases, 14%) (Supplementary Table 1). One isolate with eryth-
romycin resistance was of unknown ST type and the single 
locus variant of ST-457 and ST-40. Clonal analysis classified 7 
clonal complexes among the 34 isolates including the 4 isolates 
without ST identifications. The phylogenetic tree and eBURST 
diagram did not show a clear relatedness among the 7 clonal 
complexes (Figure 1).
Case mapping showed a wide distribution of patients with 
diphtheria in Metro Manila (Figure  2). Many patients with 
diphtheria were identified in highly populated areas. Most of 
the laboratory-confirmed cases in 2015−2017 were resident in 
areas where patients with clinical diphtheria had been observed 
in the previous 11 years. Sequence types were scattered around 
the city, with no apparent clustering of ST types.
DISCUSSION
Our study showed that diphtheria persists as an important 
public health problem in Metro Manila. The disease is most 
common among children younger than 10 years, who also have 
the highest mortality. The introduction of enhanced laboratory 
capacity showed that laboratory-diagnosed cases occurred in 
areas where clinical diphtheria cases had been found in the pre-
vious 10 years. A variety of MLST types are circulating across 
the city, particularly in densely populated areas of the city.
We observed a high number of cases and high CFRs among 
children younger than 10 years. In 2016 and 2017 this was par-
ticularly marked in children younger than 5 years. National sur-
veillance conducted by the DOH also reported a 20% increase 
in diphtheria cases in 2016 compared with cases observed in 
2015 [10]. A  contributing factor for this increased incidence 
in 2016 may be low vaccine coverage during 2014 and 2015. 
According to WHO and UNICEF (United Nations Children’s 
Fund) reports, DPT3 coverage dropped from 89% in 2013 to 
67% in 2014 and 60% in 2015, and this may have been due to 
national-level stockout of vaccine [9]. In most developed coun-
tries, the EPI led to rapid reductions in diphtheria incidence 
among children [3]. Toxigenic respiratory diphtheria among 
young children often occurs in areas where vaccine coverage 
Table 2. Characteristics of Patients With Laboratory-Confirmed Diphtheria Admitted to San Lazaro Hospital, Manila, the Philippines, between 1 December 
2015 and 9 February 2017 According to Whether They Survived or Died
Total, N Survived, n Died, n Mortality, % P RR (95% CI)
Totala 42 24 18 42.8   
Culture positive 35 19 16 45.7   
PCR positive (n = 34) 31 19 12 38.7   
Sex
 Male 17 9 8 47.1 .755 1.18 (.59–2.36)
 Female 25 15 10 40 Ref
Age group       
 <5 years 15 6 9 60 .154 2.34 (.82–7.04)
 5–9 years 5 1 4 80 3.20 (1.08–9.48)
 10–14 years 12 9 3 25 Ref
 15–19 years 7 7 0 0 N/A
 ≥20 years 3 1 2 66.8 2.67 (.74–9.60)
Living areab
 Metro Manila 28 19 9 32.1 <.05 Ref
 Outside Metro Manila 14 5 9 64.3 2.00 (1.03–3.89)
Duration of symptom
 1–4 days 25 18 7 28 <.05 Ref
 ≥4 days 17 6 11 64.7 2.31 (.12–4.75)
Underlying chronic disorders
 Any 5 1 4 80 .096 Ref
 Not present 37 23 14 37.8 2.11 (1.16–3.86)
Number of DPT dose(s)
 0 11 9 2 18.2 .082 Ref
 1 or 2 4 1 3 75 4.13 (1.03–16.6)
 3 20 12 8 40 2.2 (.55–8.74)
 Unknown/no record 7 2 5 71.4 3.93 (1.01–15.2)
DAT treatments given during the admission
 DAT given 30 19 11 36.7 .17 .62 (.32–1.23)
 DAT not given 12 5 7 58.3 Ref 
Abbreviations: CI, confidence interval; DAT, diphtheria antitoxin; DPT, diphtheria, pertussis and tetanus vaccine; N/A, not applicable; PCR, polymerase chain reaction; Ref, reference; RR, risk ratio.
aThe observation period is 1.2 year between 1 December 2015 and 9 February 2017.
bSan Lazaro Hospital is located in Metro Manila. Other data including symptoms, vital signs, and electrocardiogram findings are shown in Supplementary Table 2.
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Figure 1. A, Phylogenetic tree of Corynebacterium diphtheriae isolates based on multilocus sequence types (STs) among patients admitted to San Lazaro Hospital (SLH) 
December 2015 and February 2017. aSTs were not identified but S244/Quezon/Philippines/2016 is the single locus variant (SLV) of ST-302. S1165/Manila/Philippines/2017 
and S1166/Cavite/Philippines/2017 were SLVs of ST-457. B, The eBURST diagram demonstrates the relatedness of isolates in this study and 703 isolates as reference STs 
from the multilocus sequence typing website (http://pubmlst.org/cdiphtheriae/, accessed 15 December 2018). The primary founder STs are shown in gray, and subgroup 
founder STs are shown in black. The STs isolated in our study and SVLs of unidentified STs in our study are indicated with red and blue halos, respectively.
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is not sufficient [3, 16]. These findings suggest the need to 
strengthen and sustain vaccine coverage in this area.
Several factors may have contributed to the higher CFR in 
our study compared with those of other reports [17–20]. This 
hospital is a tertiary-care medical institution, so many cases 
were severe by the time of referral. Milder cases are likely to 
have been treated in local health facilities, possibly without 
the clinical suspicion of diphtheria. Delayed treatment was ob-
served in many cases and significantly associated with a higher 
CFR in our study. The CFR was significantly lower among DAT 
recipients compared with those without DAT treatment. The 
administration of DAT contributes to reducing mortality [21]. 
Early administration is critical because DAT is not able to neu-
tralize the toxin once the toxin has entered host cells (particu-
larly myocardial cells) [22]. DAT had not been reliably available 
in this hospital for the past 10  years. Since March 2016, the 
WHO provided DAT through the DOH in the Philippines [11]. 
A sustainable and secure supply of DAT needs to be maintained.
The CFR among those with a history of receiving 3 doses of 
primary vaccination course was not significantly lower than in 
those with no history of receiving the vaccine. Other studies 
have shown a strong association between unvaccinated status 
and death [23, 24]. The different result in this study may have 
been caused by misclassification of vaccine status due to recall 
bias. Only 8 patients were able to confirm their vaccine status 
with their immunization record card. Three patients were 
younger than 5 years and the others were aged 10−14 years. The 
finding of immunized individuals having severe toxigenic diph-
theria in these age groups indicates the need to consider en-
hancements of a school-age booster but also a booster dose for 
children younger than 5 years.
Various molecular types of diphtheria were found in this 
study with a wide distribution across Metro Manila. There was 
no apparent clustering, although we observed overlapping dis-
tributions between patients with diphtheria and densely popu-
lated areas of Metro Manila (Figure 2). ST-302 is the major ST 
type in Manila, followed by ST-67 and ST-458. ST-302 and ST-67 
were also found outside Metro Manila, and widely scattered dis-
tributions of the same ST inside Metro Manila were observed. 
The phylogenetic tree and eBURST diagram showed 7 distinct 
clonal complexes with no apparent clusters. In the MLST data-
base, these ST types have also been reported in other contin-
ents (ST-302: Germany with a travel history to Malaysia; ST-67: 
France, Belgium; ST-458: Malaysia; ST-457: Malaysia; ST-497: 
Germany; ST499: Germany). Although our study was unable 
to compare molecular type with older isolates, it is possible 
that the same strains of diphtheria have been circulating for a 
long time in the area. One study reported an outbreak strain 
Figure 2. The spatial distribution of clinically and laboratory-confirmed diphtheria cases in Metro Manila. A, The home location of the clinically diagnosed diphtheria cases 
between 1 January 2006 and 30 November 2015 (yellow dots) and culture-positive diphtheria cases by the multilocus sequence type (ST) between 1 December 2015 and 9 
February 2017 overlaid on a population-density map of Metro Manila. B, The home location of the culture-positive diphtheria cases by the multilocus STs between 1 December 
2015 and 9 February 2017 overlaid on a hotspot map created using the clinically diagnosed diphtheria cases between 1 January 2006 and 30 November 2015. Abbreviation: 
SLV, single locus variant.
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circulating in the same area over decades [14]. The genome of 
Corynebacterium species is stable and genome rearrangements 
rarely occur [25, 26].
Our study has limitations. We studied patients attending a 
single hospital in Metro Manila, which may not reflect the true 
situation across the city. It is likely that the burden of disease is 
underestimated as mild cases may not be referred to this hos-
pital. All laboratory-confirmed cases in this study were respi-
ratory toxigenic diphtheria. Cutaneous diphtheria and chronic 
rhinitis (ozenae) were not included in this study and are prob-
ably underdiagnosed in this area. We did not identify the bio-
type of the isolates but consider that MLST is more helpful in 
understanding the epidemiology of the infection [27]. We per-
formed tox-gene PCR but did not perform Elek`s test to deter-
mine the toxigenicity of the isolates. Tox-gene PCR alone is not 
able to provide a definitive confirmation of toxin production, 
but the bacteria were isolated from patients with the clinical 
picture of symptomatic respiratory diphtheria. E-tests are not 
the recommended method for MIC testing [15]. The diagnostic 
capacity for diphtheria in the Philippines is limited. A  recent 
global survey on diphtheria diagnostic capacity conducted by 
the WHO showed that significant gaps in the capacity exist in 
the Western Pacific Region. The WHO Collaborating Center for 
Diphtheria recently conducted hands-on laboratory training for 
diphtheria to build capacity in laboratory diagnosis in the re-
gion [28]. To improve diphtheria surveillance, it is necessary to 
strengthen diagnostic capacity in the Philippines.
Our study revealed that diphtheria persists as a public health 
problem in Metro Manila, the Philippines, causing preventable 
childhood deaths. Renewed efforts to improve vaccine coverage 
of the primary course of DPT are needed, as well as consider-
ation of an additional booster dose for children younger than 
5 years, encouraging education and awareness for early detec-
tion and treatment, and ensuring a sustainable supply of DAT.
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